News and Announcements
On-Demand 3D Bioprinting Company with Award-Winning Team | Developed Patented Materials and Proprietary Technology
- Published July 28, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
“A.D.A.M. presents the first-ever opportunity to print organic bones. The key reason for launching this project is to help people save their lives.
The global 3D bioprinting market is growing rapidly. According to research, it will develop very intensively up to 2024 and achieve more than $2.5B. We strongly believe in the potential of our team, which has launched successful 3D printing projects that have gained a lot of attention.
We hope that A.D.A.M. can bring this innovative endeavour to the next level.”
Denys Gurak, CEO & Co-Founder, A.D.A.M. Project
Executive Summary
A.D.A.M. (Advanced Development of Additive Manufacturing) provides on-demand 3D bioprinting services. The company uses its proprietary 3D printing technology and patented materials to manufacture bio-resorbable patient-specific implants, primarily bone implants.
A.D.A.M. currently focuses on orthopaedic implants. In the future, it intends to expand its product offerings to cover major blood vessels, heart valves, and bronchial implants.
With the company’s significant achievements over the last two years, the support received from experts on both the scientific and business sides of the project, and the positive response from the FDA, the company anticipates a relatively short and straightforward path to market approval.
Investment Highlights
- 3D-printed implant market in 2019: $1.12B. Projected market in 2027: $3.97B.
- The FDA’s positive response to A.D.A.M.’s Q-submission regarding 510(k) eligibility means that no human trials are required. There will be a decrease in the time to market from 5 years to 1.5-2 years, indicating a straightforward and streamlined regulatory process.
- A.D.A.M.’s implants are less expensive to produce than titanium implants and other alternatives. This cost efficiency creates an economic moat that directly benefits all stakeholders, including patients, insurance companies, hospitals, and investors.
- The Technology Incubation Program at the University of Connecticut has accepted A.D.A.M. and has provided access to its state-of-the-art research facilities and resources.
Investment Offering
A.D.A.M. is raising a maximum round size of $6M for its Series A preferred stock financing.
The company has already secured a lead investor for part of the round.
The Series A round will be closing on 31 July 2021.
Company Updates
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Reinventing the Condom: How an Australian Deep-Tech Startup Plans to Disrupt a $12 Billion Market
For more than half a century, the global condom industry has remained fundamentally unchanged, constrained by standard materials like latex and solid synthetic polymers. Despite widespread consumer demand for better alternatives, product design has treated the device strictly as a mechanical barrier, sacrificing feel for function. Sydney-based Eudaemon Technologies is setting out to upend that […]
Backed By Leading Investment Groups and Family Offices
